CD34 Antibody (ICO-115)

CD34, also known as Cluster of Differentiation 34, is a transmembrane phosphoglycoprotein that is primarily known for being a surface marker for hematopoietic stem cells (HSCs) and progenitor cells (1,2). The CD34 protein consists of a heavily glycosylated extracellular domain, a single-pass transmembrane helix, and a cytoplasmic tail with PDZ binding motifs (1,3). Human CD34 has two protein isoforms consisting of 385 amino acids (aa) for the canonical isoform and 328 aa for isoform 2 (3,4). The canonical CD34 isoform has calculated theoretical molecular weight of 40 kDa and an observed molecular weight of ~115 kDa (1,3,4). L-Selectin (CD62L) is the most common ligand for CD34, but it has also been shown to bind CrkL (1,3).

CD34 has commonly been used as a marker for the diagnosis and classification of various diseases and pathologies including leukemia and solitary fibrous tumor (SFT) (2,5). In terms of immunohistochemistry and histopathology, CD34 has been the most common marker for SFT and is expressed in ~79% of cases (5). In addition to its use as a cell marker, CD34-postive (CD34+) hematopoietic stem cells have been used therapeutically in patients following radiation or chemotherapy due to their regenerative potential (6). There are several clinical trials showing promising results for CD34+ cell therapy for cardiovascular diseases including heart failure, ischemia, dilated cardiomyopathy, acute myocardial infarction, and angina (6). Besides hematopoietic lineages, CD34 is also expressed in non-hematopoietic cells including mesenchymal stem cells, endothelial cells and progenitors, fibrocytes, muscle satellite cells, and some cancer stem cells (1,3). While the clinical and cell therapy applications of CD34 as a cell marker is well documented, the function of CD34 is less understood but has been implicated in many cellular processes such as adhesion, proliferation, signal transduction, differentiation, and progenitor phenotype maintenance (1,3).

References

1. Sidney, L. E., Branch, M. J., Dunphy, S. E., Dua, H. S., & Hopkinson, A. (2014). Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem cells (Dayton, Ohio), 32(6), 1380-1389. https://doi.org/10.1002/stem.1661

2. Krause, D. S., Fackler, M. J., Civin, C. I., & May, W. S. (1996). CD34: structure, biology, and clinical utility. Blood, 87(1), 1-13

3. Kapoor, S., Shenoy, S. P., & Bose, B. (2020). CD34 cells in somatic, regenerative and cancer stem cells: Developmental biology, cell therapy, and omics big data perspective. Journal of cellular biochemistry, 121(5-6), 3058-3069. https://doi.org/10.1002/jcb.29571

4. Uniprot (P28906)

5. Davanzo, B., Emerson, R. E., Lisy, M., Koniaris, L. G., & Kays, J. K. (2018). Solitary fibrous tumor. Translational gastroenterology and hepatology, 3, 94. https://doi.org/10.21037/tgh.2018.11.02

6. Prasad, M., Corban, M. T., Henry, T. D., Dietz, A. B., Lerman, L. O., & Lerman, A. (2020). Promise of autologous CD34+ stem/progenitor cell therapy for treatment of cardiovascular disease. Cardiovascular research, 116(8), 1424-1433. https://doi.org/10.1093/cvr/cvaa027

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 2 confirmed species: Human, Rat.

We have publications tested in 3 applications: FLOW, ICC/IF, Immunocytochemistry/ Immunofluorescence.

Showing Publications 1 - 8 of 8.

Publications using NBP2-29455	Applications	Species
Zhang J, Li C, Meng F et al. Functional tissue-engineered microtissue formed by self-aggregation of cells for peripheral nerve regeneration Stem cell research & therapy 2022-01-10 [PMID: 35012663] (FLOW, Rat)	FLOW	Rat
Vallant N, Sandhu B, Hamaoui K, et al Immunomodulatory Properties of Mesenchymal Stromal Cells Can Vary in Genetically Modified Rats Int J Mol Sci 2021-01-28 [PMID: 33504032] Details: Citation using the Azide and BSA Free version of this antibody.
Zhao Y, Li W, Song J et al. High Expression of EphA2 Led to Secondary Injury by Destruction of BBB Integrity though the ROCK Pathway after Diffuse Axonal Injury Neurosci. Lett. 2020-07-25 [PMID: 32721428] (ICC/IF, Rat)	ICC/IF	Rat
Qi L, Ahmadi AR, Huang J et al. Major Improvement in Wound Healing Through Pharmacologic Mobilization of Stem Cells in Severely Diabetic Rats Diabetes. [PMID: 31974141]
Li W, Chen F, Chen M et al. Psoralen mediates BMSCs osteogenic differentiation via cross-talk between Wnt/?-catenin and BMP/smad signaling pathways Research Square 2023-05-17 [PMID: 31896066] (Immunocytochemistry/ Immunofluorescence, Rat)	Immunocytochemistry/ Immunofluorescence	Rat
Zhao Y, Wei X, Song J et al. Peroxisome Proliferator-Activated Receptor g Agonist Rosiglitazone Protects Blood-Brain Barrier Integrity Following Diffuse Axonal Injury by Decreasing the Levels of Inflammatory Mediators Through a Caveolin-1-Dependent Pathway. Inflammation. 2018-11-28 [PMID: 30488141] (ICC/IF, Human)	ICC/IF	Human
Braun RK, Chetty C, Balasubramaniam V et al. Intraperitoneal injection of MSC-derived exosomes prevent experimental bronchopulmonary dysplasia Biochem. Biophys Res Commun 2018-08-06 [PMID: 30093115] (Rat) Details: This citation used the Alexa Fluor 488 version of this antibody.		Rat
Wang MY, Nestvold J, Rekdal O et al. A novel rat fibrosarcoma cell line from transformed bone marrow-derived mesenchymal stem cells with maintained in vitro and in vivo stemness properties. Exp. Cell Res. 2017-02-09 [PMID: 28189639] (Rat)		Rat

Images	Ratings	Applications	Species	Date	Details
Enlarge	5 reviewed by: Verified Customer	IHC-Fr	Rat	09/20/2017	View Summary Application Immunohistochemistry-Frozen Sample Tested Brain tissue Species Rat Lot 947-1p170111 Comments Comments Tissue Processing:The brain tissue was embedded in OCT and put in a glass beaker containing isopentane. The beaker was quickly placed in liquid nitrogen and the tissue was frozen. Removed tissue into -80 ° C for storage; Remove out the tissue from -80 ° C and equilibrate in the freezing microtome for one hour.

Array NBP2-29455

• CD34 Antibodies
• CD34 Antibody Pair
• CD34 ELISA Kit
• CD34 Lysates
• CD34 Proteins
• CD34 Proteins and Enzymes